Neutralizing Activity against BQ.1.1, BN.1, and XBB.1 in Bivalent COVID-19 Vaccine Recipients: Comparison by the Types of Prior Infection and Vaccine Formulations

Bivalent COVID-19 vaccines that contain BA.1 or BA.4/BA.5 have been introduced worldwide in response to pandemic waves of Omicron subvariants. This prospective cohort study was aimed to compare neutralizing antibodies (Nabs) against Omicron subvariants (BA.1, BA.5, BQ.1.1, BN.1, and XBB.1) before an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyun, Hak-Jun, Choi, Min-Joo, Nham, Eliel, Seong, Hye, Yoon, Jin-Gu, Noh, Ji-Yun, Cheong, Hee-Jin, Kim, Woo-Joo, Yoon, Sun-Kyung, Park, Se-Jin, Gwak, Won-Seok, Lee, June-Woo, Kim, Byoung-Guk, Song, Joon-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458764/
https://www.ncbi.nlm.nih.gov/pubmed/37631890
http://dx.doi.org/10.3390/vaccines11081320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458764/
https://www.ncbi.nlm.nih.gov/pubmed/37631890
http://dx.doi.org/10.3390/vaccines11081320

Ejemplares similares